Melinta Therapeutics

In November 2017, Deerfield committed up to $240 million to Melinta Therapeutics to fund the acquisition of the infectious disease business from The Medicines Company. Melinta is a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections. The products acquired include Vabomere, Orbactiv and Minocin IV.

Neos Therapeutics

Neos Therapeutics, Inc. is a specialty pharmaceutical company with a late-stage pipeline of innovative extended release products for the treatment of ADHD. Neos has submitted an NDA for its methylphenidate XR-ODT drug candidate for ADHD medication based on its patented XR-ODT technology. Neos’ XR-ODT and XR-Liquid product candidates provide patient-friendly dosage forms for patients who have difficulty swallowing tablets or capsules and can benefit from extended- release formulations.


KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) for the treatment of pain, ADHD and other CNS diseases through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs.


Aprecia is a specialty pharmaceutical company using its proprietary 3D printing technology to develop and manufacture pharmaceuticals. The company’s ZipDose formulation platform enables rapid dissolving forms of drugs that are beyond the formulation limits of existing fast-melt technologies. The company obtained FDA approval in 2015 for its lead product Spritam, an oral fast-melt form of levetiracetam (Keppra) for epilepsy, and is developing novel formulations of several other epilepsy drugs.

Xeris Pharmaceuticals

Deerfield invested in Xeris Pharmaceuticals through its Series C preferred financing. Xeris is developing a room temperature stable liquid formulation of glucagon that will be used in a range of products in the treatment of diabetics with hypoglycemia. The benefit of this liquid formulation is that it does not have to be refrigerated or reconstituted.


Aralez is created through the merger of POZEN Inc. and Tribute Pharmaceuticals Canada, and will be a world class special pharmaceutical company. Aralez has a proven senior management team with a diverse product portfolio of commercial assets, the anticipated launch of YOSPRALA®, and a strong balance sheet to fund additional growth opportunities.


DepoMed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. In a transformative transaction, the company agreed to acquire the U.S. rights to NUCYNTA, a drug for severe pain, from Janssen Pharmaceuticals for $1.05 billion.

To finance the purchase, Deerfield and Pharmakon structured a flexible 7 year debt facility. The total facility was $575 million of which Deerfield provided $375 million.


SteadyMed Ltd. is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined markets.

Alimera Sciences

Alimera Sciences, Inc. is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Its lead product, Iluvien, treats diabetic macular edema in patients who have previously been treated with corticosteroids.

Horizon Pharma

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On March 19th, Horizon announced the acquisition of Vidara Therapeutics International Ltd.